New Progress in the Study of Metabolic Markers of Colorectal Cancer

Release date:2019-04-15  Release:主页英文版

      

Recently, Professor LAI Maode, the president of China Pharmaceutical University, from School of Basic Medicine and Clinical Pharmacy, Professor QI Lianwen from the Clinical Metabolomics Center and Professor ZHU Yimin from Zhejiang University School of Medicine jointly reported the latest research work in the field of clinical metabolomics -- Tyrosine and Glutamineleucine are Metabolic Markers of Early-stage Colorectal Cancers. Three research groups (basic medicine, metabolomics and biostatistics) cooperated to discover  the metabolic markers of early colorectal cancer, which is expected to provide new methods and new ideas for the early diagnosis of colorectal cancer. This work was published in the top journal Gastroenterology in the field of gastrointestinal hepatology (IF 20.773, ranked first among 80 journals in the division). Ph.D. candidate LI Jiankang is the first author of this article. Professor LAI Maode, Professor Zhu Yimin and Professor Qi Lianwen are the correspondent authors of this article.


A total of 3,482 people participated in this multicentre study, including healthy people, patients with metabolic syndrome (MS), and patients with colorectal cancer (CRC). The screening group was obtained from 360 serum samples from Taizhou Hospital and Hangzhou Xiaoshan. The validation set included 1,594 samples. In addition, there is an independent queue containing 1,528 samples. The team used a metabolomics technology platform to perform non-targeted metabolomics analysis of the samples and found 30 metabolites that changed. Based on the results of linear regression analysis, targeted metabolomics analysis of Glu-Leu and tyrosine was then performed. The results suggested that the combination of Glu-Leu and tyrosine in serum is expected to be a bio-marker for early diagnosis of colorectal cancer.